TDSPharm Co

TDSPharm Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of TDSPharm Co (464280.KQ) as of Nov 5, 2026 is 6.95 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 7.59 % — a change of -8.35% (lower).

EBIT/Assets

6.95 %

YoY

-8.35%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of TDSPharm Co is 2025 6.95 % . Operating Income to Assets Ratio (EBIT/Assets) of TDSPharm Co was 2024 7.59 % . It decreases by -8.35% lower compared to the previous year.

The TDSPharm Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2021
9.26 KRW
Jan 1, 2022
12.70 KRW
Jan 1, 2023
14.77 KRW
Jan 1, 2024
7.59 KRW
Jan 1, 2025
6.95 KRW
The TDSPharm Co EBIT/Assets history
YEAREBIT/AssetsYoY
6.95 %-8.35%
7.59 %-48.62%
14.77 %+16.32%
12.70 %+37.16%
9.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TDSPharm Co Stock analysis

What does TDSPharm Co do? TDSPharm Co Ltd generates revenue through the manufacture and sale of synthetic drug displays and other finished drugs, as well as medical equipment sales. The company operates in the pharmaceutical manufacturing sector with a focus on synthetic drug displays and finished pharmaceutical products. Its e-commerce business complements traditional sales channels for medical equipment and pharmaceuticals. The primary customers include healthcare providers, hospitals, and medical institutions purchasing synthetic drug displays, finished drugs, and medical equipment. The company's product segments are synthetic drug displays, finished drugs, and medical equipment, with e-commerce serving as an additional sales channel for these segments. TDSPharm Co Ltd's revenue streams are derived from three core product categories: synthetic drug displays, finished drugs, and medical equipment. The company's e-commerce platform facilitates direct sales to healthcare institutions and medical facilities. The business model combines traditional manufacturing with digital sales channels, targeting healthcare providers as the main customer segment. The company's operations are centered on pharmaceutical manufacturing and medical equipment distribution, with e-commerce as a supplementary sales method. The company's primary revenue comes from the sale of synthetic drug displays and finished drugs, which are manufactured and sold directly to healthcare institutions. Medical equipment sales form a secondary revenue stream, while the e-commerce business provides an additional channel for all product categories. TDSPharm Co Ltd targets healthcare providers and medical institutions as its main customer base, with product segments focused on pharmaceutical manufacturing and medical equipment distribution. TDSPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TDSPharm Co stock

Operating Income to Assets Ratio (EBIT/Assets) of TDSPharm Co is 6.95 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of TDSPharm Co changed from 7.59 % to 6.95 %, representing a -8.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) TDSPharm Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s TDSPharm Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — TDSPharm Co

All Key Metrics — TDSPharm Co